細(xì)胞名稱(chēng):人胰腺癌細(xì)胞CFPAC1
產(chǎn)品規(guī)格:T25培養(yǎng)瓶x1;1.5ml凍存管x2
細(xì)胞數(shù)量:1x10^6;1x10^6
保存溫度:37℃;-198℃
運(yùn)輸方式:常溫保溫運(yùn)輸;干冰運(yùn)輸
安全等級(jí):1
用途限制:僅供科研2類(lèi)
培養(yǎng)體系:DMEM高糖+10%FBS+1%三抗
培養(yǎng)溫度:37℃
二氧化碳濃度:5%
簡(jiǎn)介:人胰腺癌細(xì)胞CFPAC1取自26歲男性供體。該細(xì)胞源于ATCC
注釋: Part of:Cancer Cell Line Encyclopedia(CCLE)project.
Part of:COSMIC cell lines project.
Part of:KuDOS 95 cell line panel.
Part of:MD Anderson Cell Lines Project.
Part of:NCI RAS program mutant KRAS cell line panel.
Doubling time:30 hours(at 17th passage),32 hours(at 74th passage)(PubMed=1692630);45 hours(PubMed=25984343).
Microsatellite instability:Stable(MSS)(Sanger).
Omics:Array-based CGH.
Omics:Deep exome analysis.
Omics:Deep proteome analysis.
Omics:Deep quantitative proteome analysis.
Omics:Deep RNAseq analysis.
Omics:DNA methylation analysis.
Omics:Metabolome analysis.
Omics:Protein expression by reverse-phase protein arrays.
Omics:Proteome analysis by 2D-DE/MS.
Omics:shRNA library screening.
Omics:SNP array analysis.
Omics:Transcriptome analysis.
Misspelling:CFPANC1;In CGH-DB 164-1.
基因突變
Homozygous for CFTR p.Phe508del(c.1521_1523delCTT)(PubMed=15463957;ATCC).
Heterozygous for KRAS p.Gly12Val(c.35G>T)(PubMed=11169959;PubMed=11787853;PubMed=15367885;Cosmic-CLP).
Homozygous for SMAD4 deletion(PubMed=10408907;PubMed=11169959;PubMed=11787853;PubMed=15367885).
Homozygous for TP53 p.Cys242Arg(c.724T>C)(PubMed=11169959;PubMed=11787853;PubMed=15367885;Cosmic-CLP).
HLA信息:/
STR信息
Amelogenin X,Y
CSF1PO 10
D2S441 10,14
D2S1338 18,23
D3S1358 16
D5S818 10,11
D6S1043 20
D7S820 8,10
D8S1179 11,15
D12S391 17
D13S317 12
D16S539 9,11
D18S51 12
D19S433 13,15
D21S11 30,31.2
FGA 21,22
Penta D 11,13
Penta E 10,12
TH01 8
TPOX 8
vWA 17
參考文獻(xiàn)
PubMed=28196595;DOI=10.1016/j.ccell.2017.01.005
Li J.,Zhao W.,Akbani R.,Liu W.,Ju Z.,Ling S.,Vellano C.P.,Roebuck P.,Yu Q.,Eterovic A.K.,Byers L.A.,Davies M.A.,Deng W.,Gopal Y.N.V.,Chen G.,von Euw E.M.,Slamon D.J.,Conklin D.,Heymach J.V.,Gazdar A.F.,Minna J.D.,Myers J.N.,Lu Y.,Mills G.B.,Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)
PubMed=30894373;DOI=10.1158/0008-5472.CAN-18-2747
Dutil J.,Chen Z.,Monteiro A.N.,Teer J.K.,Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res.79:1263-1273(2019)
PubMed=31068700;DOI=10.1038/s41586-019-1186-3
Ghandi M.,Huang F.W.,Jane-Valbuena J.,Kryukov G.V.,Lo C.C.,McDonald E.R.III,Barretina J.,Gelfand E.T.,Bielski C.M.,Li H.,Hu K.,Andreev-Drakhlin A.Y.,Kim J.,Hess J.M.,Haas B.J.,Aguet F.,Weir B.A.,Rothberg M.V.,Paolella B.R.,Lawrence M.S.,Akbani R.,Lu Y.,Tiv H.L.,Gokhale P.C.,de Weck A.,Mansour A.A.,Oh C.,Shih J.,Hadi K.,Rosen Y.,Bistline J.,Venkatesan K.,Reddy A.,Sonkin D.,Liu M.,Lehar J.,Korn J.M.,Porter D.A.,Jones M.D.,Golji J.,Caponigro G.,Taylor J.E.,Dunning C.M.,Creech A.L.,Warren A.C.,McFarland J.M.,Zamanighomi M.,Kauffmann A.,Stransky N.,Imielinski M.,Maruvka Y.E.,Cherniack A.D.,Tsherniak A.,Vazquez F.,Jaffe J.D.,Lane A.A.,Weinstock D.M.,Johannessen C.M.,Morrissey M.P.,Stegmeier F.,Schlegel R.,Hahn W.C.,Getz G.,Mills G.B.,Boehm J.S.,Golub T.R.,Garraway L.A.,Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
PubMed=31978347;DOI=10.1016/j.cell.2019.12.023
Nusinow D.P.,Szpyt J.,Ghandi M.,Rose C.M.,McDonald E.R.III,Kalocsay M.,Jane-Valbuena J.,Gelfand E.,Schweppe D.K.,Jedrychowski M.,Golji J.,Porter D.A.,Rejtar T.,Wang Y.K.,Kryukov G.V.,Stegmeier F.,Erickson B.K.,Garraway L.A.,Sellers W.R.,Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402(2020)
細(xì)胞操作說(shuō)明書(shū)下載:
細(xì)胞操作說(shuō)明書(shū)